Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression
Sanjay Chandrasekaran, Maiko Sasaki, Christopher D. Scharer, et al.
Molecular Cancer Research (2019) Vol. 17, Iss. 12, pp. 2395-2409
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 435
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck, Matthew W. D. Perry, Jennifer R. Brown, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 10, pp. 741-769
Open Access | Times Cited: 343
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 181-197
Closed Access | Times Cited: 207
Immunomodulation by targeted anticancer agents
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, et al.
Cancer Cell (2020) Vol. 39, Iss. 3, pp. 310-345
Open Access | Times Cited: 181
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 141
A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy
Fushun Fan, Pei Liu, Rudi Bao, et al.
Cancer Research (2021) Vol. 81, Iss. 24, pp. 6233-6245
Open Access | Times Cited: 128
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 100
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Xiangyu Wu, Tianhang Li, Rui Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 70
The Importance of Being PI3K in the RAS Signaling Network
Cristina Cuesta, Cristina Arévalo-Alameda, Esther Castellano
Genes (2021) Vol. 12, Iss. 7, pp. 1094-1094
Open Access | Times Cited: 73
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Ryan J. Duchatel, Evangeline R. Jackson, Sarah Parackal, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 6
Open Access | Times Cited: 15
Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway
Xiaobo Luo, Yan Qiu, Zackary R. Fitzsimonds, et al.
Oncogene (2024) Vol. 43, Iss. 6, pp. 388-394
Closed Access | Times Cited: 10
Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Shogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa
Science Immunology (2025) Vol. 10, Iss. 105
Closed Access | Times Cited: 1
The Landscape of PIK3CA Mutations in Colorectal Cancer
Ioannis A. Voutsadakis
Clinical Colorectal Cancer (2021) Vol. 20, Iss. 3, pp. 201-215
Closed Access | Times Cited: 47
Playing hide and seek: Tumor cells in control of MHC class I antigen presentation
Marlieke L.M. Jongsma, Jacques Neefjes, Robbert M. Spaapen
Molecular Immunology (2021) Vol. 136, pp. 36-44
Open Access | Times Cited: 38
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Ioannis A. Voutsadakis
Current Oncology (2022) Vol. 29, Iss. 3, pp. 1390-1407
Open Access | Times Cited: 23
EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
James Kang, Albert I. Ko, Sang Hoon Kil, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1878, Iss. 1, pp. 188827-188827
Closed Access | Times Cited: 23
G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I via PI3K/Akt Activation in Bladder Cancer
X.F. Steven Zheng, Jiawei Chen, Minhua Deng, et al.
Advanced Science (2023) Vol. 11, Iss. 7
Open Access | Times Cited: 14
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Sanjay Chandrasekaran, Christopher Ronald Funk, T. Kleber, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 26
Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy
Angèle Luby, Marie‐Clotilde Alves‐Guerra
Cancers (2021) Vol. 13, Iss. 23, pp. 5912-5912
Open Access | Times Cited: 25
Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization
Qi Zhang, Bingqiu Xiu, Li-Yi Zhang, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e004666-e004666
Open Access | Times Cited: 17
Challenges and Prospects in HER2-Positive Breast Cancer-Targeted Therapy
Xi‐Yin Li, Xueying Zhang, Saige Yin, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 207, pp. 104624-104624
Open Access
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy
Louisa Alim, Siddharth Adityan, Rui Chen, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 187, pp. 118141-118141
Closed Access
Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer
Marco A. De Velasco, Yurie Kura, Kazutoshi Fujita, et al.
International Journal of Urology (2024) Vol. 31, Iss. 4, pp. 307-324
Open Access | Times Cited: 3
Tumor hypermetabolism confers resistance to immunotherapy
Arthur Liu, Michael A. Curran
Seminars in Cancer Biology (2020) Vol. 65, pp. 155-163
Closed Access | Times Cited: 23
Hypochlorous acid-modified human serum albumin suppresses MHC class II - dependent antigen presentation in pro-inflammatory macrophages
Agnes Ulfig, Verian Bader, Marharyta Varatnitskaya, et al.
Redox Biology (2021) Vol. 43, pp. 101981-101981
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top